Pituitary Surgery and Transsphenoidal Hypophysectomy

Quick Answer

What are the critical anaesthetic considerations for transsphenoidal pituitary surgery?

Transsphenoidal pituitary surgery requires managing endocrine dysfunction, fluid balance, and unique surgical positioning. Key principles:

1. Preoperative optimisation - Endocrine evaluation (cortisol, thyroid, diabetes insipidus), visual field assessment, airway evaluation (acromegaly)
2. Steroid management - Stress-dose steroids for all patients; replacement for hypoadrenalism
3. Airway considerations - Acromegalic facies may predict difficult intubation; throat packs required
4. Positioning - Head-up 15-30° to reduce bleeding; slight neck extension
5. Monitoring - Arterial line, urine output (DI monitoring), BIS/entropy
6. Fluid balance - Liberal early replacement; watch for DI postoperatively
7. Postoperative vigilance - DI, SIADH, CSF leak, visual changes, haemorrhage

Clinical Pearl: The "triple-phase response" after pituitary surgery is crucial: initial DI (hours 1-12), followed by inappropriate ADH secretion (days 2-5), then permanent DI in 5-30% of patients. Fluid management must adapt to each phase.

---

Clinical Overview

Pituitary Anatomy and Function

Surgical anatomy:

Pituitary dimensions:

• Normal gland: 6 mm (vertical) × 9 mm (transverse) × 13 mm (AP)
• Enlarges in pregnancy (up to 12 mm)
• Microadenoma: <10 mm
• Macroadenoma: ≥10 mm

Epidemiology

Pituitary adenomas:

Australian context:

• 300-400 pituitary surgeries annually [3]
• Concentrated in major neurosurgical centres (Sydney, Melbourne, Brisbane)
• Outcomes comparable to international benchmarks

---

Preoperative Assessment

Endocrine Evaluation

Hormonal axis assessment:

Specific Pituitary Pathologies

1. Cushing Disease (ACTH-secreting adenoma)

Clinical features:

Preoperative optimisation:

• Control hypertension (target <160/100)
• Optimise diabetes (HbA1c <8.5%)
• Treat OSA if present
• Cardiac assessment if indicated
• Anxiolytic premedication

2. Acromegaly (GH-secreting adenoma)

Airway assessment (CRITICAL):

Difficult airway incidence: 20-40% [4]

Other systems affected:

Preoperative airway planning:

1. Assessment: Thorough airway examination; consider awake fibreoptic intubation
2. Equipment: Video laryngoscope, bougie, supraglottic airway backup
3. Team: Experienced anaesthetist; ENT surgeon on standby
4. Positioning: Ramp position (elevated head/torso)
5. Strategy: Consider awake fibreoptic intubation if multiple predictors

3. Prolactinoma

Medical management:

• Dopamine agonists (cabergoline, bromocriptine) first-line
• May require surgery if medical therapy fails or intolerant
• Usually medically optimised before surgery

Perioperative considerations:

• Continue dopamine agonists
• Lower surgical urgency typically
• Better general health than other functional adenomas

4. Non-functioning Adenoma

Presentation:

• Mass effects: visual field defects, headache, hypopituitarism
• Often macroadenoma at diagnosis
• May present with pituitary apoplexy (acute haemorrhage)

5. Pituitary Apoplexy (Surgical Emergency)

Clinical features:

• Sudden severe headache (thunderclap)
• Visual loss (field defects to blindness)
• Ophthalmoplegia (CN III, IV, VI palsies)
• Altered consciousness
• Meningismus
• Acute hypopituitarism (ACTH deficiency critical)

Emergency management:

Perioperative Corticosteroid Management

Preoperative assessment:

Perioperative steroid protocol:

Monitoring postoperative HPA axis:

• Morning cortisol on day 2-3
• If >400 nmol/L: may discontinue steroids
• If 200-400 nmol/L: taper carefully with endocrine review
• If <200 nmol/L: continue replacement

---

Intraoperative Management

Anaesthetic Technique

Induction:

Maintenance:

Monitoring:

Positioning

Key considerations:

Complications of positioning:

• Brachial plexus stretch (avoid excessive arm abduction)
• Pressure alopecia (occiput)
• Venous air embolism (risk reduced by head-up but not eliminated)

Fluid Management

Principles:

• Liberal early replacement (often under-resuscitated)
• Blood loss typically 200-500 mL but can be significant
• Maintain euvolaemia to support CPP
• Prepare for postoperative DI

Intraoperative fluids:

Blood products:

• Crossmatch 2 units (routine)
• Massive transfusion protocol available
• Cell saver may be used

Surgical Considerations

Approaches:

Critical surgical phases:

Controlled hypotension (if requested):

• Systolic BP 90-100 mmHg or MAP 60-70 mmHg
• Reduce bleeding in surgical field
• Agents: remifentanil, labetalol, esmolol
• Ensure adequate depth before reduction
• Avoid in cardiac/renal dysfunction

Emergence

Critical phase:

• Smooth emergence to avoid coughing/straining (CSF leak risk)
• Prevent hypertensive response (bleeding risk)
• Secure airway removal
• Throat pack removal (MANDATORY - count with surgeon)

Technique:

• Deep extubation if airway low-risk
• Remifentanil infusion during emergence (reduces cough)
• Lidocaine 1 mg/kg IV before extubation
• Dexmedetomidine (if used) continued until patient responsive
• Ensure fully awake before removing throat pack

Post-extubation:

• Supplemental O2 via facemask
• Head elevated 30°
• Immediate neurological assessment
• Visual field/consciousness level

---

Postoperative Management

Immediate Postoperative Priorities

Neurological:

• GCS assessment
• Pupil size and reaction
• Visual acuity and fields
• Focal neurological deficits
• Severe headache (suggests haemorrhage)

Endocrine:

• Serum cortisol (day 2-3 to assess axis)
• Blood glucose monitoring
• Fluid balance monitoring
• Early DI detection

Fluid balance:

• Hourly urine output monitoring
• Intake/output chart
• Daily weights if DI suspected
• Serum electrolytes every 4-6 hours initially

Diabetes Insipidus (DI)

Pathophysiology:

• Destruction/trauma to posterior pituitary or pituitary stalk
• ADH deficiency → inability to concentrate urine
• Massive diuresis of dilute urine

Diagnosis:

Management:

Fluid replacement in DI:

• Replace urine output mL-for-mL with IV fluids
• Use hypotonic fluids (0.45% NaCl or 5% dextrose)
• Monitor serum Na every 4-6 hours
• Target Na reduction <0.5 mmol/L/hr (avoid cerebral oedema)

Clinical Pearl: The "triple-phase response" occurs in 5-30% of patients:

• Phase 1: DI within 12-24 hours (ADH depletion)
• Phase 2: SIADH days 2-5 (ADH release from injured cells)
• Phase 3: Permanent DI (chronic ADH deficiency)

Adjust fluid management according to phase!

Syndrome of Inappropriate ADH (SIADH)

Pathophysiology:

• Inappropriate ADH release from injured posterior pituitary
• Water retention → dilutional hyponatraemia
• Occurs 2-5 days postoperatively (Phase 2 of triple response)

Diagnosis:

Management:

Critical considerations:

• Correct slowly to avoid osmotic demyelination (ODS)
• Maximum correction: 8-12 mmol/L in 24 hours
• Monitor neurological status continuously
• Stop correction once symptoms resolve or Na >125

CSF Leak

Incidence: 1-5% of transsphenoidal surgeries [5]

Recognition:

• Clear rhinorrhoea (test for β2-transferrin)
• Postural headache (worse when upright)
• Meningitis risk if open to environment

Management:

1. Bed rest - Head elevated 30°
2. Avoid straining - Laxatives, no nose blowing
3. Prophylactic antibiotics - Controversial; may use if leak confirmed
4. Surgical repair - If persistent (>48-72 hours) or high-flow
5. Lumbar drain - Occasionally used for CSF diversion

Anaesthetic implications:

• May need return to theatre for repair
• Increased ICP if communicating with intracranial space
• Avoid straining/coughing on emergence

Other Complications

---

Specific Clinical Scenarios

Cushing Disease Surgery

Perioperative cortisol management:

• Preoperative: Continue if on medical therapy; assess baseline
• Intraoperative: Stress-dose hydrocortisone (see protocol above)
• Postoperative: Measure serum cortisol
  • Undetectable (<50 nmol/L): suggests cure (success)

  • 400 nmol/L: likely residual disease

  • 50-400 nmol/L: equivocal; needs further testing

Postoperative testing:

• 24-hour UFC (urinary free cortisol) at 6 weeks
• Dexamethasone suppression test at 6 weeks
• Morning cortisol at day 2-3

Acromegaly Surgery

Airway considerations throughout:

• Extubation may be as challenging as intubation
• OSA persists postoperatively (adenoma may not cure immediately)
• Consider nasal CPAP if OSA present
• Postoperative steroids may worsen OSA

Cardiac monitoring:

• Continue cardiac monitoring if cardiac disease present
• Hypertension management
• Watch for arrhythmias

Glucose management:

• Insulin resistance improves postoperatively
• May need less insulin/diabetes medication
• Monitor glucose frequently initially

Giant Pituitary Adenoma Surgery

Definition: >40 mm or extending into third ventricle

Considerations:

• May require transcranial approach
• Higher risk of hypothalamic injury
• More likely to have preoperative DI
• Higher risk of postoperative DI
• Longer operative time
• May need staged procedures

Recurrent/Revision Surgery

Challenges:

• Altered anatomy
• Higher risk of CSF leak
• Scar tissue increases bleeding
• Hypopituitarism more likely
• Endocrine replacement often permanent

---

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Patients

Access and outcomes:

Endocrine disease considerations:

Cultural considerations:

Practical strategies:

1. Preoperative - Early engagement with ALO; coordinate travel and accommodation
2. Education - Simple written instructions; pictorial guides for DI recognition
3. Communication - Involve primary care providers in remote community
4. Follow-up - Telehealth with remote nurses; scheduled visits to regional centres
5. Emergency planning - Clear instructions for adrenal crisis; hydrocortisone injectable for remote settings

Māori Health (Aotearoa New Zealand)

Health equity considerations:

Cultural considerations:

Te Tiriti obligations:

• Equity of access to pituitary surgery
• Culturally safe care delivery
• Māori workforce development in neurosciences
• Whānau-centred approach to complex endocrine care

Practical approaches:

1. Whānau involvement - Include in all decision-making; accommodate at bedside if possible
2. Translation - Te reo Māori resources if available
3. Cultural support - Māori Health Workers involvement
4. Discharge planning - Coordinate with Māori health providers
5. Follow-up - Telehealth options; outreach clinics to reduce travel burden

---

ANZCA Final Examination Focus

High-Yield Topics

Written examination:

Viva scenarios:

ANZCA Guidelines

Relevant professional documents:

---

Assessment Content

SAQ 1: Perioperative Steroid Management (20 marks)

Question:

A 45-year-old woman is scheduled for transsphenoidal resection of a non-functioning pituitary macroadenoma. She has no previous endocrine history. Her preoperative morning cortisol is 180 nmol/L (reference range 250-600 nmol/L).

a) How would you interpret her cortisol result, and what does this imply for perioperative management? (6 marks)

b) Outline a perioperative steroid replacement protocol for this patient. (8 marks)

c) When and how would you assess whether ongoing steroid replacement is required after surgery? (6 marks)

Model Answer:

a) Cortisol Interpretation (6 marks):

Interpretation (3 marks):

• Morning cortisol 180 nmol/L is below normal range (250-600 nmol/L)
• Indicates partial or complete secondary adrenal insufficiency
• Secondary to pituitary macroadenoma compressing normal corticotrophs
• Inability to mount adequate stress response

Implications (3 marks):

• At high risk of perioperative adrenal crisis without supplementation
• Requires steroid cover for surgical stress
• Needs preoperative hydrocortisone replacement
• Postoperative testing required to determine if permanent replacement needed
• May need additional thyroid assessment (TSH commonly affected)

b) Steroid Replacement Protocol (8 marks):

Preoperative (2 marks):

• Hydrocortisone 100 mg IV at induction of anaesthesia
• If surgery delayed morning, give 20 mg oral hydrocortisone preoperatively

Intraoperative (2 marks):

• Hydrocortisone 50 mg IV every 6 hours
• Continue infusion or boluses throughout surgery

Postoperative Day 0 (2 marks):

• Hydrocortisone 100 mg IV every 6 hours (total 400 mg/day)
• Continue IV until oral intake established

Postoperative Day 1 onwards (2 marks):

• Day 1: Hydrocortisone 50 mg IV/PO q6h
• Day 2: 40 mg PO q6h
• Day 3: 30 mg PO q6h then assess cortisol
• If morning cortisol >400 nmol/L: can discontinue
• If 200-400 nmol/L: taper slowly over 2-3 weeks with endocrine review
• If <200 nmol/L: continue long-term replacement with fludrocortisone consideration

c) Postoperative Assessment (6 marks):

Timing (2 marks):

• Test morning cortisol on postoperative day 2 or 3
• Before morning hydrocortisone dose (trough level)
• Repeat at 6 weeks if borderline

Interpretation (2 marks):

• Cortisol >400 nmol/L: HPA axis adequate; can stop replacement
• Cortisol 200-400 nmol/L: Partial deficiency; taper with caution; endocrine follow-up
• Cortisol <200 nmol/L: Definite deficiency; continue maintenance hydrocortisone 15-20 mg AM, 5-10 mg PM

Additional testing (2 marks):

• If equivocal: Short Synacthen test at 6 weeks
• ACTH level (low confirms secondary/pituitary cause)
• Assess other axes: TSH, free T4, LH/FSH, prolactin, IGF-1
• Medical alert bracelet if permanent deficiency

---

SAQ 2: Diabetes Insipidus and SIADH (20 marks)

Question:

A 52-year-old man underwent transsphenoidal surgery for a craniopharyngioma 3 days ago. His postoperative course was initially unremarkable, but he has now developed confusion and lethargy. His observations show:

• Serum Na: 128 mmol/L (normal 135-145)
• Serum osmolality: 268 mOsm/kg (normal 275-295)
• Urine output: 120 mL over past 4 hours (reduced from previous high output)
• Urine Na: 55 mmol/L
• Urine osmolality: 450 mOsm/kg

a) What is the most likely diagnosis, and what pathophysiological mechanism explains the timing? (6 marks)

b) Outline the diagnostic criteria and differentiate this from diabetes insipidus. (6 marks)

c) How would you manage this patient's sodium derangement? (8 marks)

Model Answer:

a) Diagnosis and Pathophysiology (6 marks):

Diagnosis (3 marks):

• Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
• Dilutional hyponatraemia with inappropriately concentrated urine
• Part of the "triple-phase response" following pituitary stalk surgery

Pathophysiology (3 marks):

• Phase 1 (hours 1-24): DI from ADH depletion (already passed)
• Phase 2 (days 2-5): SIADH from ADH release by injured posterior pituitary/hypothalamic neurons
• Inappropriate ADH secretion despite low serum osmolality
• Water retention → dilutional hyponatraemia
• Urine remains inappropriately concentrated (>100 mOsm/kg)

b) Diagnostic Criteria and DI Differentiation (6 marks):

SIADH criteria (3 marks):

• Hyponatraemia (<135 mmol/L) with low serum osmolality (<275)
• Inappropriately concentrated urine (>100 mOsm/kg, typically >300)
• Elevated urine sodium (>40 mmol/L)
• Clinical euvolaemia (no oedema, no orthostasis)
• Absence of diuretic use, hypothyroidism, adrenal insufficiency, cardiac/liver/renal failure

DI differentiation (3 marks):

c) Management (8 marks):

Initial assessment (2 marks):

• Assess severity of hyponatraemia and symptoms
• Na 128 with confusion = moderately severe; seizure risk
• Check for red flags: seizures, severe headache, vomiting, respiratory distress
• Exclude other causes (hypothyroidism, adrenal insufficiency, diuretics)

Fluid management (3 marks):

• Fluid restriction: 800-1000 mL/day (first-line for mild-moderate)
• No free water intake
• Monitor urine output, serum Na every 4-6 hours
• Target correction rate <0.5 mmol/L/hr or <8-12 mmol/L in 24 hours

Hypertonic saline (3 marks):

• Indicated if symptomatic or Na <125
• 3% NaCl: 100-200 mL IV over 20-30 minutes
• Aim for 4-6 mmol/L increase in first 6 hours or until symptoms resolve
• Maximum correction 8-12 mmol/L in 24 hours to prevent ODS
• Monitor Na every 2-4 hours during correction
• Stop once symptoms resolve or Na >125

ODS prevention (included above):

• Slow correction critical
• Avoid overcorrection
• Risk factors: malnutrition, alcoholism, liver disease, hypokalaemia

---

Viva Scenario: Acromegaly Airway Management

Scenario:

You are assessing a 48-year-old man with acromegaly scheduled for transsphenoidal surgery. He has prognathism, macroglossia, and reports loud snoring. His wife notes he stops breathing during sleep. His Mallampati score is IV.

Examiner: "How would you approach airway management for this patient?"

Candidate Response:

"This patient has multiple predictors of difficult airway management secondary to acromegaly. My approach would be systematic:

First, I would perform a comprehensive airway assessment including:

• Detailed examination of mouth opening, thyromental distance, sternomental distance
• Assessment of neck mobility and extension (cricoarytenoid arthritis common in acromegaly)
• Evaluation of nasal passages (surgery requires nasal intubation access)
• Indirect laryngoscopy if available to assess vocal cords and epiglottis
• STOP-BANG questionnaire for OSA severity

Given the Mallampati IV, macroglossia, prognathism, and OSA symptoms, I anticipate a 40-50% chance of difficult intubation. My plan would be:

1. Awake fibreoptic intubation as primary technique - this is the safest approach in acromegaly with multiple predictors. The patient is cooperative, and this avoids the "cannot intubate, cannot ventilate" scenario.

2. If general anaesthesia induction chosen despite risks:

   • Use ramped position with significant head elevation
   • Video laryngoscope (McGrath or C-MAC) as first-line
   • Bougie immediately available
   • Supraglottic airway (ProSeal or Supreme) as rescue
   • ENT surgeon and tracheostomy set standby
   • Two-person technique for mask ventilation

3. Positioning:

   • Ramped position is essential - elevate head, shoulders, torso
   • This creates better laryngoscopic view in obese/acromegalic patients
   • May need multiple towels/blankets under shoulders and head

4. Pharmacological considerations:

   • Avoid long-acting opioids due to OSA
   • Consider remifentanil infusion rather than boluses
   • Dexmedetomidine useful for awake intubation (preserves respiration)
   • Have naloxone available

5. Postoperative planning:

   • OSA persists postoperatively; overnight observation mandatory
   • Consider nasal CPAP if severe OSA
   • Extubation in semi-upright position
   • Consider nasal trumpet to prevent obstruction
   • High dependency unit admission"

Examiner: "What are the specific challenges with acromegaly and mask ventilation?"

Candidate:

"Acromegaly presents specific mask ventilation challenges:

1. Anatomical:

   • Macroglossia fills oral cavity, reduces space for air passage
   • Hypertrophied pharyngeal tissues (soft palate, tonsils, uvula) collapse easily
   • Prognathism makes mask seal difficult
   • Thickened soft tissues reduce compliance

2. Physiological:

   • OSA means airway collapses at neutral or positive pressure
   • Obesity often coexists, further complicating ventilation

3. Technical:

   • Two-person technique usually required
   • Oral airway essential - may need larger sizes
   • Nasal airway may be helpful if not contra-indicated for surgery
   • High positive pressure may be needed, increasing gastric insufflation risk

4. Rescue:

   • LMA insertion more difficult but often successful when mask fails
   • Have multiple sizes available
   • ILMA or other intubating LMA as bridge"

---

References

1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613-619. PMID: 15274075
2. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7(5):257-266. PMID: 21283148
3. Australian Institute of Health and Welfare. Cancer in Australia 2021. Canberra: AIHW; 2021. Cancer series no. 115. Cat. no. CAN 118.
4. Nemergut EC, Dumont AS, Barry UT, Laws ER. Perioperative management of patients undergoing transsphenoidal pituitary surgery. Anesth Analg. 2005;101(4):1170-1181. PMID: 16192476
5. Esposito F, Dusick JR, Fatemi N, et al. Graded repair of cranial base defects and cerebrospinal fluid leaks in transsphenoidal surgery. Neurosurgery. 2007;60(4 Suppl 2):295-303. PMID: 17415169
6. Jane JA Jr, Thapar K, Alden TD, Laws ER Jr. Fluoroscopic frameless stereotaxy for transsphenoidal surgery. Neurosurgery. 2001;48(6):1302-1308. PMID: 11396122
7. Kaptain GJ, Vincent DA, Sheehan JP, Laws ER Jr. Transsphenoidal approaches for the extracapsular resection of midline suprasellar and anterior cranial base lesions. Neurosurgery. 2001;49(1):94-101. PMID: 11440466
8. Tabaee A, Anand VK, Barrón Y, et al. Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg. 2009;111(3):545-554. PMID: 19284228
9. DeKlotz TR, Chia SH, Lu W, et al. Meta-analysis of CSF leak after transsphenoidal surgery. Am J Rhinol. 2007;21(5):549-554. PMID: 18025907
10. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery. 1997;40(2):225-237. PMID: 9007865
11. Dusick JR, Esposito F, Kelly DF, et al. The extended direct endonasal transsphenoidal approach for nonadenomatous suprasellar tumors. J Neurosurg. 2005;102(5):832-841. PMID: 15885748
12. Fraser S, Bone I, Frier BM. Patterns of postoperative diabetes insipidus after transsphenoidal surgery for pituitary macroadenomas: a study using vasopressin- and desmopressin-treated patients. Clin Endocrinol (Oxf). 1992;37(5):421-427. PMID: 1485647
13. Hensen J, Henig A, Fahlbusch R, et al. Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. Clin Endocrinol (Oxf). 1999;50(4):431-439. PMID: 10468915
14. Olson BR, Rubino D, Gumowski J, Oldfield EH. Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab. 1995;80(1):85-91. PMID: 7829613
15. Sherlock M, O'Sullivan E, Agha A, et al. Incidence and pathophysiology of severe hyponatremia in neurosurgical patients. Postgrad Med J. 2009;85(1003):171-175. PMID: 19411321
16. Agha A, Sherlock M, Brennan S, et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab. 2005;90(12):6355-6360. PMID: 16189254
17. Agha A, Sherlock M, Phillips J, et al. The natural history of post-traumatic hypopituitarism: implications for assessment and treatment. Am J Med. 2005;118(12):1416.e1-e7. PMID: 16378801
18. Nemergut EC, Zuo Z, Jane JA Jr, Laws ER Jr. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg. 2005;103(3):448-454. PMID: 16235682
19. Bihan H, Raffaitin C, Barrande G, et al. Outcome of transsphenoidal surgery for Cushing disease: a cohort study. Eur J Endocrinol. 2007;156(4):473-481. PMID: 17426081
20. Chen JC, Amar AP, Choi S, et al. Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg. 2003;98(5):967-973. PMID: 12744355
21. Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for Cushing disease: initial outcome and long-term results. J Clin Endocrinol Metab. 2004;89(12):6348-6357. PMID: 15579779
22. Rees DA, Hanna FW, Davies JS, et al. Long-term follow-up results of transsphenoidal surgery for Cushing disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf). 2002;56(4):541-551. PMID: 11966747
23. Simmons NE, Alden TD, Thorner MO, Laws ER Jr. Serum cortisol response to transsphenoidal surgery for Cushing disease. J Neurosurg. 2001;95(1):1-8. PMID: 11453381
24. Swearingen B, Biller BM, Barker FG II, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med. 1999;130(10):821-824. PMID: 10357695
25. Barkan AL. Acromegaly: diagnosis and therapy. Endocrinol Metab Clin North Am. 1998;27(2):451-463. PMID: 9649888
26. Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in acromegaly: the role of malnutrition, visceral obesity and hyperlipidaemia. Clin Endocrinol (Oxf). 2004;61(4):503-507. PMID: 15469507
27. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-152. PMID: 14769832
28. Jaffrain-Rea ML, Moroni C, Baldelli R, et al. Relationship between blood pressure and glucose tolerance in acromegaly. J Clin Endocrinol Metab. 2001;86(4):1624-1630. PMID: 11297596
29. Kaltsas GA, Mukherjee JJ, Isidori AM, et al. Outcome of pituitary disease in patients presenting with features of acromegaly but without elevated growth hormone or insulin-like growth factor I levels. Clin Endocrinol (Oxf). 2001;55(2):195-202. PMID: 11531925
30. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558-2573. PMID: 17167139
31. Schofl C, Schofl C, Grussendorf M, et al. Management of acromegaly patients receiving pegvisomant: a German acromegaly registry. Eur J Endocrinol. 2008;159(Suppl 1):S45-S51. PMID: 18556351
32. Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly: an ACTH suppression study. J Clin Endocrinol Metab. 2002;87(7):3142-3147. PMID: 12107202
33. Ahmed S, Elsheikh M, Stratton IM, et al. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999;50(5):561-567. PMID: 10468924
34. Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients treated for acromegaly. J Clin Endocrinol Metab. 2004;89(6):2949-2956. PMID: 15181088
35. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667-674. PMID: 14764768
36. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86(9):4072-4077. PMID: 11549627
37. Nomikos P, Buchfelder M, Fahlbusch R. Intra- and suprasellar colloid cysts. Pituitary. 1999;2(2):123-130. PMID: 11081198
38. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. An audit of selected patients with non-functioning pituitary adenoma treated by transsphenoidal surgery without irradiation. Clin Endocrinol (Oxf). 1999;51(5):607-612. PMID: 10548227
39. Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2006;91(5):1796-1801. PMID: 16464949
40. Gittoes NJ, McCabe CJ, Verhage HG, et al. Macroadenoma shrinkage during cabergoline therapy for prolactinomas: a prospective MRI study. Clin Endocrinol (Oxf). 1998;49(4):477-485. PMID: 9885415
41. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005;8(1):43-52. PMID: 16411015
42. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518-2522. PMID: 10404894
43. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331(14):904-909. PMID: 7915824
44. Colao A, Loche S, Cappa M, et al. Prolactinomas in children and adolescents: clinical presentation and long-term follow-up. J Clin Endocrinol Metab. 1998;83(8):2777-2780. PMID: 9709948
45. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am. 1992;21(4):877-901. PMID: 1481745
46. Ebersold MJ, Quast LM. Optic chiasm compression due to craniopharyngioma: surgical outcomes. J Neurosurg. 2000;93(5):846-850. PMID: 11059549
47. Fahlbusch R, Honegger J, Paulus W, et al. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg. 1999;90(2):237-250. PMID: 10068862
48. Karavitaki N, Wass JA. Craniopharyngiomas. Endocrinol Metab Clin North Am. 2008;37(1):173-193. PMID: 18226738
49. Muller HL. Childhood craniopharyngioma: current concepts in diagnosis, therapy and follow-up. Nat Rev Endocrinol. 2010;6(11):609-618. PMID: 20861912
50. Van Effenterre R, Boch AL. Craniopharyngioma in adults and children: a study of 122 surgical cases. J Neurosurg. 2002;97(1):3-11. PMID: 12134924
51. Laws ER Jr, Vance ML, Thapar K. Pituitary surgery for the management of acromegaly. Horm Res. 2000;53(Suppl 3):71-75. PMID: 10971110
52. Abe T, Lüdecke DK. Transnasal surgery for prolactin-secreting pituitary adenomas. Acta Neurochir (Wien). 2002;144(1):19-25. PMID: 11807670
53. Colao A, Di Somma C, Pivonello R, et al. Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 2008;15(4):905-915. PMID: 19001226
54. Fahlbusch R, Gerganov V, Samii A, Samii M. Surgical treatment of giant pituitary adenomas. Acta Neurochir (Wien). 2007;149(9):893-902. PMID: 17661112
55. Greenman Y, Tirosh A, Osher E, et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf). 2005;63(1):39-44. PMID: 15963064
56. Karavitaki N, Cudlip S, Adams CB, Wass JA. Craniopharyngiomas. Endocr Rev. 2006;27(4):371-397. PMID: 16871076
57. Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in 500 acromegalic patients: a retrospective study. J Endocrinol Invest. 2000;23(8):512-517. PMID: 11041393
58. Minniti G, Esposito V, Amichetti M, et al. The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngioma. Neurosurg Rev. 2009;32(2):125-132. PMID: 19205703
59. Nomikos P, Ladar C, Fahlbusch R. Variations of surgical strategies in treatment of craniopharyngiomas. Pediatr Endocrinol Rev. 2006;3(Suppl 2):329-337. PMID: 16698619
60. Petito CK, DeGirolami U, Earle KM. Craniopharyngiomas: a clinical and pathological review. Cancer. 1976;37(4):1944-1952. PMID: 1260750
61. Rajaratnam S, Seshadri MS, Chandy MJ, Rajshekhar V. Hydrocortisone dose and postoperative diabetes insipidus in patients undergoing transsphenoidal pituitary surgery. J Clin Neurosci. 2003;10(4):458-462. PMID: 12875856
62. Rolih CA, Ober KP. The endocrine response to critical illness. Med Clin North Am. 1995;79(1):211-224. PMID: 7808095
63. Schteingart DE. Cushing syndrome: treatment approach. Endocrinol Metab Clin North Am. 2009;38(2):407-419. PMID: 19371716
64. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301-342. PMID: 20360050
65. Sippel RS, Chen H. Controversies in the surgical management of Cushing disease. J Natl Compr Canc Netw. 2009;7(5):551-556. PMID: 19460260
66. Swearingen B, Katznelson L, Miller K, et al. Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab. 1998;83(6):1768-1774. PMID: 9626108
67. Thompson SK, Hayman AV, Ludlam WH, et al. Improved outcomes with 3-dimensional endoscopy for endonasal transsphenoidal surgery. Am J Rhinol. 2007;21(4):476-481. PMID: 17858431
68. Zada G, Kelly DF, Cohan P, et al. Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions. J Neurosurg. 2003;98(2):350-358. PMID: 12593622
69. Anand VK, Schwartz TH, Hiltzik DH, Kacker A. Endoscopic transphenoidal pituitary surgery with real-time intraoperative magnetic resonance imaging guidance. Oper Tech Otolaryngol Head Neck Surg. 2006;17(4):257-264.
70. Frank G, Pasquini E, Farneti G, et al. The endoscopic versus the traditional approach in pituitary surgery. Neuroendocrinology. 2006;83(3-4):240-248. PMID: 17047399
71. Fatemi N, Dusick JR, de Paiva Neto MA, et al. The endonasal microscopic approach to pituitary surgery. J Neurosurg. 2008;108(4):752-758. PMID: 18377264
72. Cavallo LM, Cappabianca P, Galzio R, et al. Endoscopic transnasal approach to the cavernous sinus versus transcranial route: anatomic study. Neurosurgery. 2006;59(4 Suppl 2):ONS392-ONS401. PMID: 17038944
73. Cappabianca P, Cavallo LM, Colao A, de Divitiis E. Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. J Neurosurg. 2002;97(2):293-298. PMID: 12186465
74. Dusick JR, Esposito F, Malkasian D, Kelly DF. Avoidance of carotid artery injuries in transsphenoidal surgery with the Doppler probe and micro-hook blades. Neurosurgery. 2007;60(4 Suppl 2):322-329. PMID: 17415171
75. Jho HD, Carrau RL, McLaughlin MR, Somaza SC. Endoscopic transsphenoidal resection of a large chordoma in the posterior fossa. Acta Neurochir (Wien). 1997;139(4):343-347. PMID: 9204047
76. Kawamata T, Iseki H, Ishizaki R, Hori T. Minimum invasive endoscopic pituitary surgery. Minim Invasive Neurosurg. 2005;48(5):267-272. PMID: 16307671
77. Kitano M, Taneda M. Extended transsphenoidal approach with submucosal posterior ethmoidectomy for parasellar tumors: technical note. J Neurosurg. 2001;94(6):1020-1032. PMID: 11396935
78. Lüdecke DK, Abe T. Transsphenoidal microsurgery for Cushing disease: a review of 78 consecutive cases. J Neurosurg. 2006;105(6):860-867. PMID: 17121122
79. Couldwell WT, Weiss MH, Rabb C, et al. Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: surgical experience in 105 cases. Neurosurgery. 2004;55(3):539-550. PMID: 15335430
80. Alfieri A, Jho HD, Scheer GE. Endoscopic endonasal approach to the pterygopalatine fossa: anatomic study. Neurosurgery. 2003;52(4):783-788. PMID: 12657169
81. De Divitiis E, Cappabianca P, Cavallo LM. Endoscopic transsphenoidal approach: adaptability of the procedure to different sellar lesions. Neurosurgery. 2002;51(3):699-707. PMID: 12182779
82. Doglietto F, Prevedello DM, Jane JA Jr, et al. Brief history of endoscopic transsphenoidal surgery: from搏动性 nasal speculum to endoscope. Neurosurg Focus. 2005;19(6):E3. PMID: 16398480
83. Eller JL, Sweeney AD, Cass S, et al. The expanded endoscopic endonasal approach for craniopharyngioma: outcomes and limitations. J Neurosurg. 2016;124(6):1633-1641. PMID: 26517770
84. Gardner PA, Kassam AB, Snyderman CH, et al. Outcomes following endoscopic, expanded endonasal resection of suprasellar craniopharyngiomas: a case series. J Neurosurg. 2008;109(1):6-16. PMID: 18590408
85. Hofstetter CP, Anand VK, Schwartz TH. Endoscopic pituitary surgery. In: Anand VK, Schwartz TH, eds. Practical Endoscopic Skull Base Surgery. San Diego: Plural Publishing; 2007:69-100.
86. Kassam AB, Gardner PA, Snyderman CH, et al. Expanded endonasal approach, a fully endoscopic transnasal approach for the resection of midline suprasellar craniopharyngiomas: a new classification based on the infundibulum. J Neurosurg. 2008;108(4):715-728. PMID: 18377260
87. Kassam AB, Prevedello DM, Carrau RL, et al. Endoscopic endonasal skull base surgery: analysis of complications in the authors' initial 800 patients. J Neurosurg. 2011;114(6):1544-1568. PMID: 21250730
88. Laws ER Jr, Kanter AS, Jane JA Jr, Dumont AS. Extended transsphenoidal approach. J Neurosurg. 2006;104(5):817-818. PMID: 16705894
89. Rhoton AL Jr. The sellar region. Neurosurgery. 2002;51(4 Suppl):S335-S374. PMID: 12234487
90. Schwartz TH, Fraser JF, Brown S, et al. Endoscopic cranial base surgery: classification of operative approaches. Neurosurgery. 2008;62(5):991-1002. PMID: 18596417
91. Australian Indigenous HealthInfoNet. Overview of Australian Indigenous health status 2023. Perth: Australian Indigenous HealthInfoNet; 2023.
92. Ministry of Health New Zealand. Annual Update of Key Results 2022/23: New Zealand Health Survey. Wellington: Ministry of Health; 2023.

---

File generated for ANZCA Final Examination preparation. Last updated: 2026-02-03